JP2011524904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524904A5 JP2011524904A5 JP2011514600A JP2011514600A JP2011524904A5 JP 2011524904 A5 JP2011524904 A5 JP 2011524904A5 JP 2011514600 A JP2011514600 A JP 2011514600A JP 2011514600 A JP2011514600 A JP 2011514600A JP 2011524904 A5 JP2011524904 A5 JP 2011524904A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- nitrogen
- optionally substituted
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 46
- 229910052757 nitrogen Inorganic materials 0.000 claims 38
- 229910052717 sulfur Inorganic materials 0.000 claims 35
- 229910052760 oxygen Inorganic materials 0.000 claims 34
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 33
- 125000005842 heteroatom Chemical group 0.000 claims 33
- 239000001301 oxygen Chemical group 0.000 claims 33
- 239000011593 sulfur Chemical group 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000002723 alicyclic group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000001931 aliphatic group Chemical group 0.000 claims 12
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 CCC(C1)*CCN1c([s]c(-c1nnc[n]1)c1-c(cc2)c(*)cc2Cl)c1C#N Chemical compound CCC(C1)*CCN1c([s]c(-c1nnc[n]1)c1-c(cc2)c(*)cc2Cl)c1C#N 0.000 description 5
- LVQANDFSOGVEHX-UHFFFAOYSA-N CC(C)(C1)OCCN1c([s]c(-c1nnc[nH]1)c1-c(ccc(Cl)c2)c2Cl)c1C#N Chemical compound CC(C)(C1)OCCN1c([s]c(-c1nnc[nH]1)c1-c(ccc(Cl)c2)c2Cl)c1C#N LVQANDFSOGVEHX-UHFFFAOYSA-N 0.000 description 1
- RYONLBOWCIKRIL-UHFFFAOYSA-N CC1(c([s]c(N2CCOCC2)c2C#N)c2-c(ccc(Cl)c2)c2Cl)NC(C)=CCC1=N Chemical compound CC1(c([s]c(N2CCOCC2)c2C#N)c2-c(ccc(Cl)c2)c2Cl)NC(C)=CCC1=N RYONLBOWCIKRIL-UHFFFAOYSA-N 0.000 description 1
- IPQBZBUACCKVJZ-UHFFFAOYSA-N COc1cc(-c2c(C3(N)NC=NC3)[s]c(N3CCOCC3)c2C#N)ccc1 Chemical compound COc1cc(-c2c(C3(N)NC=NC3)[s]c(N3CCOCC3)c2C#N)ccc1 IPQBZBUACCKVJZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13248408P | 2008-06-19 | 2008-06-19 | |
| US61/132,484 | 2008-06-19 | ||
| PCT/US2009/003607 WO2009154741A1 (en) | 2008-06-19 | 2009-06-17 | Thiophene or thiazole derivatives and their use as pi3k inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524904A JP2011524904A (ja) | 2011-09-08 |
| JP2011524904A5 true JP2011524904A5 (enExample) | 2012-10-18 |
| JP5596026B2 JP5596026B2 (ja) | 2014-09-24 |
Family
ID=41010579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514600A Active JP5596026B2 (ja) | 2008-06-19 | 2009-06-17 | チオフェン又はチアゾール誘導体及びｐｉ３ｋ阻害剤としてのそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8183240B2 (enExample) |
| EP (1) | EP2313399B1 (enExample) |
| JP (1) | JP5596026B2 (enExample) |
| KR (1) | KR20110018451A (enExample) |
| CN (1) | CN102066365A (enExample) |
| AU (1) | AU2009260782B2 (enExample) |
| BR (1) | BRPI0914223A2 (enExample) |
| CA (1) | CA2727069A1 (enExample) |
| CL (1) | CL2010001474A1 (enExample) |
| CO (1) | CO6331431A2 (enExample) |
| CR (1) | CR20110032A (enExample) |
| EA (1) | EA201170052A1 (enExample) |
| ES (1) | ES2491522T3 (enExample) |
| GE (1) | GEP20125650B (enExample) |
| IL (1) | IL210055A0 (enExample) |
| MA (1) | MA32468B1 (enExample) |
| MX (1) | MX2010014125A (enExample) |
| NZ (1) | NZ589844A (enExample) |
| UA (1) | UA106206C2 (enExample) |
| WO (1) | WO2009154741A1 (enExample) |
| ZA (1) | ZA201008875B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| ES2491522T3 (es) * | 2008-06-19 | 2014-09-08 | Millennium Pharmaceuticals, Inc. | Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP2012516329A (ja) * | 2009-01-30 | 2012-07-19 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用 |
| EP2603216A4 (en) * | 2010-08-11 | 2013-12-18 | Millennium Pharm Inc | HETEROARYLE AND USES THEREOF |
| WO2012021696A1 (en) * | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2012021611A1 (en) * | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP5726635B2 (ja) | 2010-08-25 | 2015-06-03 | 株式会社Ｎｔｔドコモ | マルチモードフロントエンド回路 |
| CA2814688A1 (en) | 2010-10-13 | 2012-04-19 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN102503930B (zh) * | 2011-10-28 | 2014-07-02 | 浙江大学 | 3,4,5,-三取代氨基噻吩类化合物及其制备和用途 |
| EP2790705B1 (en) | 2011-12-15 | 2017-12-06 | Novartis AG | Use of inhibitors of the activity or function of pi3k |
| JP2015503505A (ja) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヘテロアリールおよびその使用 |
| CN104204805B (zh) | 2012-03-14 | 2017-08-01 | 萨克生物研究学院 | 腺病毒肿瘤诊断法 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR20150130451A (ko) | 2013-03-15 | 2015-11-23 | 제넨테크, 인크. | 암 치료 방법 및 항암제 내성 예방을 위한 방법 |
| CN106164071B (zh) * | 2014-02-14 | 2019-09-10 | 不列颠哥伦比亚大学 | 作为治疗剂的人雄激素受体dna-结合结构域(dbd)化合物及其使用方法 |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| CA3144848C (en) * | 2019-06-28 | 2023-11-21 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
| CN110759900B (zh) * | 2019-10-25 | 2021-07-30 | 沈阳药科大学 | 噻吩类化合物的制备方法和用途 |
| EP4077302A1 (en) | 2019-12-20 | 2022-10-26 | Bayer Aktiengesellschaft | Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD275870A1 (de) | 1988-09-27 | 1990-02-07 | Univ Leipzig | Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen |
| EP1742627A4 (en) | 2004-05-06 | 2009-08-26 | Plexxikon Inc | PDE4B HEMMER AND ITS USE |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| US20090076009A1 (en) * | 2006-05-03 | 2009-03-19 | Arnould Jean-Claude Retired | Thiazole derivatives and their use as anti-tumour agents |
| CA2660758A1 (en) * | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| CA2704711C (en) * | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| ES2491522T3 (es) * | 2008-06-19 | 2014-09-08 | Millennium Pharmaceuticals, Inc. | Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K |
-
2009
- 2009-06-17 ES ES09767054.1T patent/ES2491522T3/es active Active
- 2009-06-17 CA CA2727069A patent/CA2727069A1/en not_active Abandoned
- 2009-06-17 UA UAA201100563A patent/UA106206C2/ru unknown
- 2009-06-17 EA EA201170052A patent/EA201170052A1/ru unknown
- 2009-06-17 NZ NZ589844A patent/NZ589844A/xx not_active IP Right Cessation
- 2009-06-17 CN CN2009801230046A patent/CN102066365A/zh active Pending
- 2009-06-17 GE GEAP200912065A patent/GEP20125650B/en unknown
- 2009-06-17 US US12/456,455 patent/US8183240B2/en active Active
- 2009-06-17 BR BRPI0914223A patent/BRPI0914223A2/pt not_active IP Right Cessation
- 2009-06-17 EP EP09767054.1A patent/EP2313399B1/en active Active
- 2009-06-17 JP JP2011514600A patent/JP5596026B2/ja active Active
- 2009-06-17 MX MX2010014125A patent/MX2010014125A/es active IP Right Grant
- 2009-06-17 KR KR1020117001175A patent/KR20110018451A/ko not_active Ceased
- 2009-06-17 AU AU2009260782A patent/AU2009260782B2/en not_active Ceased
- 2009-06-17 WO PCT/US2009/003607 patent/WO2009154741A1/en not_active Ceased
-
2010
- 2010-12-09 ZA ZA2010/08875A patent/ZA201008875B/en unknown
- 2010-12-16 IL IL210055A patent/IL210055A0/en unknown
- 2010-12-17 CL CL2010001474A patent/CL2010001474A1/es unknown
- 2010-12-23 CO CO10161488A patent/CO6331431A2/es active IP Right Grant
-
2011
- 2011-01-13 MA MA33511A patent/MA32468B1/fr unknown
- 2011-01-17 CR CR20110032A patent/CR20110032A/es not_active Application Discontinuation
-
2012
- 2012-04-18 US US13/449,341 patent/US8440664B2/en active Active
-
2013
- 2013-04-01 US US13/854,409 patent/US20130217689A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524904A5 (enExample) | ||
| JP2011510080A5 (enExample) | ||
| RU2008144008A (ru) | Способ получения высокоочищенного прасугреля или его кислотно-аддитивной соли | |
| JP2020502130A5 (enExample) | ||
| RU2014131065A (ru) | Димерные соединения-агонисты рецептора fgf ( fgfr ), способ их получения и их терапевтическое применение | |
| RU2013117441A (ru) | Пролекарства, содержащие конъюгат эксендин-линкер | |
| HRP20161306T1 (hr) | Dimerni spojevi kao agonisti receptora fgf (fgfr), postupak za njihovu pripravu i njihova terapijska uporaba | |
| JP2005524631A5 (enExample) | ||
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| WO2010059239A3 (en) | Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders | |
| JP2013502431A5 (enExample) | ||
| JP2016506935A5 (enExample) | ||
| JP2008508303A5 (enExample) | ||
| JP2019529444A5 (enExample) | ||
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| JP7764041B2 (ja) | 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物 | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2007502263A5 (enExample) | ||
| CN103265560A (zh) | 棉酚/棉酮衍生物及其制备方法和抗肿瘤药物中的应用 | |
| RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| RU2012137245A (ru) | Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций | |
| RU2007118691A (ru) | Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника | |
| RU2006130686A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) |